ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

TRB191

A development code.

Its studies are mostly in Small Cell Lung Carcinoma, led by Novartis.

Furthest: phase 1, since Oct 26, 20261 company-led study, 1 open or runningNext primary completion: Jul 30, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 1since Oct 26, 2026Oct 26, 2026Jul 30, 2030phase 1 · NCT07908667

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07908667 · 120 planned · Israel

Ahead

  1. Jul 30, 2030Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07908667

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908667Small Cell Lung Carcinoma · Israel1RecruitingJul 30, 2030120

How it is read

Names in the registry

  • “TRB191”, 1 entry

Codes read as this program: TRB191.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.